ArticleClinical rheumatology2026
The incidence of clinically diagnosed chronic obstructive pulmonary disease in patients with spondyloarthritis compared to matched population-based references: a register-based study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
INTRODUCTION/
objectiveTo estimate and compare the incidence of chronic obstructive pulmonary disease (COPD) in patients with spondyloarthritis (SpA) to matched population-based references.
methodsPatients with ≥ 1 SpA-diagnosis from an outpatient department of rheumatology/internal medicine (≥ 17 years at diagnosis) between January 1, 2000, and June 30, 2005, were identified in a regional healthcare register. From the same register, five controls without SpA-diagnosis were matched to each SpA-case on age at the first ever SpA-diagnosis for the case, municipality of residence at this time, and sex. SpA-cases and controls were followed from Jan 1, 2006, until first occurrence of either COPD (diagnosed in primary or secondary inpatient/outpatient care), rheumatoid arthritis diagnosis, moving from the region, death, or Dec 31, 2018. The incidence rates of COPD in SpA-cases and controls, overall and by age-groups and sex, and the corresponding incidence rate ratios, were estimated.
resultsA total of 1083/4950 SpA-cases and controls were followed in the present study for 11,790.9/58,876.4 person-years, with 38/220 incident COPD-cases respectively. The estimated incidence of COPD in SpA-cases was 3.22 (95% CI 2.28-4.42) per 1000 person-years, with an incidence rate ratio compared to controls of 0.86 (95% CI 0.59-1.22). Similarly, there were no significant differences in the incidence of COPD in patients with SpA compared to controls in any age group and in both sexes.
conclusionsIn this register-based cohort study the incidence of COPD in patients with SpA was similar to that in matched population-based references, overall and after stratification for sex and age-groups. Key Points • Spondyloarthritis (SpA) has been associated with comorbidities, e.g. cardiovascular disease. However, evidence regarding the relation between SpA and chronic obstructive pulmonary disease (COPD) is limited. • To our knowledge, this is the first study to investigate the incidence of COPD in a population-based cohort of patients with SpA in general and compare it to the background population. • Using a regional register of primary and specialized care, we found no difference in COPD incidence between those diagnosed with SpA and matched population-based references, overall and after stratification for sex and age group. • The results of the present study suggest that there may not be an association between SpA and COPD. However, further studies in other countries and settings are needed.
Indexed as
Identifiers
42681260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.